Daniel Q Huang, Liang Shen, Wah Wah Phyo, Gavin Cloherty, Emily K Butler, Mary C Kuhns, Anne L McNamara, Vera Holzmayer, Jeffrey Gersch, Mark Anderson, Wei Lyn Yang, Jing Hieng Ngu, Jason Chang, Jessica Tan, Taufique Ahmed, Yock Young Dan, Yin Mei Lee, Guan Huei Lee, Poh Seng Tan, Mark Muthiah, Htet Toe Wai Khine, Chris Lee, Amy Tay, Seng Gee Lim
BACKGROUND: HBeAg loss is an important endpoint for antiviral therapy in chronic hepatitis B (CHB), however there are no reliable biomarkers to identify patients who will respond to the addition of pegylated interferon to nucleos(t)ide analogue (NA) therapy. AIM: To evaluate the use of serum biomarkers to predict HBeAg loss. METHODS: HBeAg positive CHB participants on NAs who switched-to or added-on 48 weeks pegylated interferon alpha2b (clinicaltrial...
April 17, 2024: Antiviral Research